Cutaneous lupus erythematosus after treatment with paclitaxel and bevacizumab for metastatic breast cancer: A case report

Journal of Medical Case Reports

Volumn 5, Issue , 2011, Pages

  Vihinen, Pia ^a   Paija, Outi ^a   Kivisaari, Atte ^a   Koulu, Leena ^a   Aho, Heikki ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTINUCLEAR ANTIBODY; BEVACIZUMAB; CANDESARTAN HEXETIL; CETIRIZINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; EXTRACTABLE NUCLEAR ANTIBODY; FLUOROURACIL; HYDROCHLOROTHIAZIDE; LA ANTIBODY; METOPROLOL; PACLITAXEL; PROGESTERONE RECEPTOR; RO ANTIBODY; TAMOXIFEN; THYROXINE; UNCLASSIFIED DRUG;

AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIBODY BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOTHYROIDISM; LIVER METASTASIS; LUNG METASTASIS; MAMMOGRAPHY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; NECK METASTASIS; NEEDLE BIOPSY; PRIORITY JOURNAL; SIDE EFFECT; SKIN BIOPSY; SKIN LUPUS ERYTHEMATOSUS; SPLEEN CANCER; SPLEEN METASTASIS; TREATMENT DURATION;

EID: 79959553913     PISSN: None     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/1752-1947-5-243     Document Type: Article

References (14)

1. Skin sensitivity to UVB irradiation in systemic lupus erythematosus is not related to the level of apoptosis induction in keratinocytes. E Reefman H Kuiper MF Jonkman PC Limburg CG Kallenberg M Bijl, Rheumatology 2006 45 538 544 10.1093/rheumatology/kei249 16352635
2. Drug-induced lupus erythematosus. P Sarzi-Puttini F Atzeni F Capsoni E Lubrano A Doria, Autoimmunity 2005 38 507 518 10.1080/08916930500285857 16373256 (Pubitemid 43101785)
3. Taxol-induced acral erythema. D de Agrila JD Dominquez L Iglesias, Dermatology 1996 192 377 378 10.1159/000246419 8864381 (Pubitemid 26238243)
4. Scleroderma-like cutaneous lesions induced by paclitaxel: a case study. I Kupfer X Balguerie P Courville P Chinet P Joly, J Am Acad Dermatol 2003 48 279 281 10.1067/mjd.2003.30 12582404 (Pubitemid 36232332)
5. Stevens-Johnson syndrome induced by paclitaxel in a patient with squamous cell carcinoma of the lung: a case report. A Hiraki K Aoe T Murakami T Maeda R Eda H Takeyama, Anticancer Res 2004 24 1135 1137 15154637 (Pubitemid 38624952)
6. Paclitaxel-induced cutaneous lupus erythematosus in patients with serum anti-SSA/Ro antibody. A Adachi T Horikawa, J Dermatol 2007 34 473 476 10.1111/j.1346-8138.2007.00313.x 17584326 (Pubitemid 46956593)
7. Mechanisms of disease: angiogenesis and the management of breast cancer. S Banerjee M Dowsett A Ashworth LA Martin, Nat Clin Pract Oncol 2007 4 536 550 17728712 (Pubitemid 47351464)
8. Paclitaxel plus bevacizumab versus paclitaxel for metastatic breast cancer. K Miller M Wang J Gralow M Dickler M Cobleigh EA Perez T Shenkier D Cella NE Davidson, N Engl J Med 2007 357 2666 2676 10.1056/NEJMoa072113 18160686
9. Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. P Schöffski H Dumez P Clement A Hoeben H Prenen P Wolter S Joniau T Roskams H Van Poppel, Ann Oncol 2006 17 1185 1196 10.1093/annonc/mdj133 16418310 (Pubitemid 44288208)
10. Docetaxel (Taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases. M Chem AN Crowson M Woofter MB Luca CM Magro, J Rheumatol 2004 31 818 820 15088316 (Pubitemid 38451277)
11. Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. V Gotlib S Khaled I Lapko N Mar MW Saif, Anticancer Drugs 2006 17 1227 1229 10.1097/01.cad.0000231481.07654.fc 17075324 (Pubitemid 44673405)
12. Incidence and management of cutaneous toxicities associated with cetuximab. MF Saif R Kim, Expert Opin Drug Saf 2007 6 175 182 10.1517/14740338.6.2.175 17367263 (Pubitemid 46380811)
13. Immunolocalization and expression of vascular endothelial growth factor receptors (VEGFRs) and neuropilins (NRPs) on keratinocytes in human epidermis. XY Man XH Yang SQ Cai YG Yao M Zheng, Mol Med 2006 12 127 136 17088944 (Pubitemid 44646341)
14. Serum concentrations of vascular endothelial growth factor in collagen diseases. K Kikuchi M Kubo T Kadono N Yazawa H Ihn K Tamaki, Br J Dermatol 1998 139 1049 1051 10.1046/j.1365-2133.1998.02563.x 9990370 (Pubitemid 29010544)